# A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

> **NCT06401603** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Chronic Myeloid Leukemia
- Philadelphia Chromosome-Positive Acute Myeloid Leukemia

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Listaftoclax
- **DRUG:** Olverembatinib

## Key facts

- **NCT ID:** NCT06401603
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-06
- **Primary completion:** 2027-01-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06401603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06401603, "A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06401603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*